One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for whom surgery has failed or is not an option, a post-hoc analysis of a Phase 3 clinical trial shows. Signifor was found to normalize urinary cortisol levels and ease…
People diagnosed with Cushing’s disease during childhood may experience lowered pituitary hormones long after receiving surgery, as well as mood and cognitive disorders, a long-term follow-up study shows. The study, “Long-Term Outcome in Patients After Treatment for Cushing’s Disease in Childhood,” was published in the journal PLoS…
A diagnostic technique called bilateral inferior petrosal sinus sampling (BIPSS), which measures the levels of the adrenocorticotropic hormone (ACTH) produced by the pituitary gland, should only be used to diagnose cyclic Cushing’s syndrome patients during periods of cortisol excess, a case report shows. When it…
People with Cushing’s syndrome often experience a rise in blood pressure that puts them at a significant risk of cardiovascular ills, but most improve within 10 days after surgery to treat their hypercortisolism, a study found. Nonetheless, fewer than half see their blood pressure normalized within one year of surgical…
Cushing’s disease patients who are treated with cabergoline while undergoing conventional fractionated radiotherapy have a higher risk of disease recurrence after initial remission, a small study has found. The study, “Cabergoline may act as a radioprotective agent in Cushing’s disease,” was published in Clinical Endocrinology. Radiation…
On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends on their specific disease subtype, a review study from Germany reports. Cushing’s disease patients — those with a tumor in the pituitary gland — wait the longest for a…
A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in people with endogenous Cushing’s syndrome has begun dosing patients in Europe, the company announced. The GRACE trial (NCT03697109) will be conducted at 62 sites in the United States,…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as Isturisa — for the treatment of adults with Cushing’s syndrome. Osilodrostat, formerly known as LCI699, is an oral treatment that inhibits an enzyme called 11-beta-hydroxylase, which is involved in…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Get regular updates to your inbox.